Patients with traditional treatment options who have run out or have refractory blood cancer now have a lifeline thanks to CAR T-cell therapy, a totally new approach to treating hematological malignancies diligently. This review examines the medical effect, clinical orbit, and use of CAR T-cell treatment for a series of hematological malformations, with attention to leukemia and lymphoma. Genetic engineering to express synthetic receptors to modify autologous T cells that specifically target tumor-bound antigens, such as CD19 B-cell maturity antigen (BCMA), and CAR T-cell therapy provides targeted and effective antitumor reactions. The most important applications are in aggressive B-cell lymphomas such as diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), which perform high total reaction and full remission rates, and B-cell acute lymphoblast surcmia. FDA-approved innovative medications have changed the treatment paradigms and have shown the long-term potential for adoption of cell immunotherapy, including tisagenlecleusel, axicabtagne ciloleucel, and brexucabtaes autolucle. Despite these successes, cytokine release syndrome (CRS), neurotoxicity, antigen flight, T-cell deficiency, and logistical boundaries in cell production are the most important problems related to CAR T-cell treatment. In order to improve safety, durability, access, and innovation, double-angled CARs are developed, and universal “outside the shelf” accessories are actively used. In addition, synergistic therapeutic benefits are performed by integration with cinema inhibitors, kinase inhibitors and immune checkpoint inhibitors. The study examines the new potential for CAR T-cell therapy in tumor treatment, historically difficult to treat, such as acute myeloid leukemia (AML) and T-cell leukemia, where antigen specificity and safety are still important obstacles. To increase its use and improve patient outcomes worldwide, further innovation and clinical research are necessary.